The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has given GenVec Inc. a Phase I Small Business Innovation and Research (SBIR) grant to support the development of adenovector-based vaccines for HSV-2 virus. This virus is responsible for a majority of the genital herpes cases.